EUVIMEDEUVIMED entdecken
Crossref

RNA-Based Therapeutics for the Treatment of Parkinson’s Disease

Paris M. Kiehl, Rachel VanKeulen-Miller, Eshan A. Narasipura, Owen S. Fenton

ACS Nano Medicine · 13.11.2026

DOI: 10.1021/acsnanomed.6c00223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 13.11.2026. Verfasst von Paris M. Kiehl und 3 weiteren Autor:innen. Die Arbeit nennt 272 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a progressive neurological condition characterized by degeneration of dopaminergic neurons in the substantia nigra, accompanied by α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation, ultimately leading to hallmark motor symptoms including tremors and bradykinesia. RNA-based therapeutics are an emerging avenue for the treatment of PD due to their ability to modulate gene expression and therefore address the underlying molecular mechanisms driving disease progression. These approaches may modulate gene expression in key PD cell types. RNA-based therapeutics have been used to target dopaminergic neurons to strategically downregulate α-synuclein aggregation, balance growth signaling, inhibit apoptosis, or alleviate mitochondrial stress. Some strategies work to decrease neuroinflammation through microglia targeting. Additionally, some strategies seek to regulate dopamine signaling within serotonergic neurons and striatal medium spiny neurons. In this review, we summarize diverse RNA modalities that have been leveraged to address PD pathophysiology and explore nonviral carriers that have emerged to facilitate RNA delivery into target cells. We then discuss RNA-based therapeutic targeting strategies in preclinical and clinical studies and examine the trajectory of the field as these nanomedicines are increasingly applied to the treatment of PD.

Zitieren

APA

Kiehl, P. M., VanKeulen-Miller, R., Narasipura, E. A., & Fenton, O. S. (2026). RNA-Based Therapeutics for the Treatment of Parkinson’s Disease. ACS Nano Medicine. https://doi.org/10.1021/acsnanomed.6c00223

Vancouver

Kiehl PM, VanKeulen-Miller R, Narasipura EA, Fenton OS. RNA-Based Therapeutics for the Treatment of Parkinson’s Disease. ACS Nano Medicine. 2026. doi:10.1021/acsnanomed.6c00223

BibTeX
@article{Kiehl2026,
  author = {Kiehl, Paris M. and VanKeulen-Miller, Rachel and Narasipura, Eshan A. and Fenton, Owen S.},
  title = {RNA-Based Therapeutics for the Treatment of Parkinson’s Disease},
  journal = {ACS Nano Medicine},
  year = {2026},
  doi = {10.1021/acsnanomed.6c00223}
}
Kostenlos starten →